Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ulf Boemer is active.

Publication


Featured researches published by Ulf Boemer.


Acta Crystallographica Section D-biological Crystallography | 2011

A crystallographic fragment screen identifies cinnamic acid derivatives as starting points for potent Pim-1 inhibitors.

Michèle N. Schulz; Jörg Fanghänel; Martina Schäfer; Volker Badock; Hans Briem; Ulf Boemer; Duy Nguyen; Manfred Husemann; Roman Hillig

A crystallographic fragment screen was carried out to identify starting points for the development of inhibitors of protein kinase Pim-1, a potential target for tumour therapy. All fragment hits identified via soaking in this study turned out to bind to the unusually hydrophobic pocket at the hinge region. The most potent fragments, two cinnamic acid derivatives (with a best IC(50) of 130 µM), additionally form a well defined hydrogen bond. The balance between hydrophobic and polar interactions makes these molecules good starting points for further optimization. Pim-2 inhibitors from a recently reported high-throughput screening campaign also feature a cinnamic acid moiety. Two of these Pim-2 inhibitors were synthesized, their potencies against Pim-1 were determined and their cocrystal structures were elucidated in order to determine to what degree the binding modes identified by fragment screening are conserved in optimized inhibitors. The structures show that the cinnamic acid moieties indeed adopt the same binding mode. Fragment screening thus correctly identified binding modes which are maintained when fragments are grown into larger and higher affinity inhibitors. The high-throughput screening-derived compound (E)-3-{3-[6-(4-aminocyclohexylamino)-pyrazin-2-yl]phenyl}acrylic acid (compound 1) is the most potent inhibitor of the cinnamic acid series for which the three-dimensional binding mode is known (IC(50) = 17 nM, K(d) = 28 nM). The structure reveals the molecular basis for the large gain in potency between the initial fragment hit and this optimized inhibitor.


Archive | 2003

Thiazolidinones and the use therof as polo-like kinase inhibitors

Wolfgang Schwede; Volker Schulze; Knut Eis; Bernd Buchmann; Hans Briem; Gerhard Siemeister; Ulf Boemer; Karsten Parczyk


Archive | 2006

Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs

Ulrich Lücking; Duy Nguyen; Arne Von Bonin; Oliver Von Ahsen; Martin Krüger; Hans Briem; Georg Kettschau; Olaf Prien; Anne Mengel; Krolikiewicz Konrad; Ulf Boemer; Ulrich Bothe; Ingo Hartung


Archive | 2007

Substituted sulphoximines as tie2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same

Ingo Hartung; Georg Kettschau; Hans Briem; Karl-Heinz Thierauch; Ulrich Luecking; Ulf Boemer; Martin Krueger


Cancer Research | 2018

Abstract 1887: Preclinical evaluation of a novel interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor in combination with PI3K inhibitor copanlisib or BTK inhibitors in ABC-DLBCL

Martin Lange; Antje Margret Wengner; Ulrich Bothe; Ulf Boemer; Reinhard Nubbemeyer; Holger Siebeneicher; Holger Steuber; Judith Guenther; Lisette Potze; Nicole Schmidt; Oliver Politz; Wolf-Dietrich Doecke; Eleni Lagkadinou; Thomas Matthias Zollner; Franz von Nussbaum; Dominik Mumberg; Andreas Steinmeyer; Michael Brands; Karl Ziegelbauer


Archive | 2008

Compuestos derivados de pirazolopiridina sustituida;composicion farmaceutica que los comprende;metodo de preparacion de los compuestos ,compuestos intermediarios;y su uso en el tratamiento de enfermedades,tales como tumores,artritis reumatoide,enfermedades del crecimiento vascular desregulado, entre otras.

Hans Briem; Ingo Hartung; Georg Kettschau; Stuart Ince; Karl-Heinz Thierauch; Ulf Boemer


Archive | 2008

Substituted tricyclic heterocyclic compounds for use as egfr inhibitors

Hartmut Schirok; Ying Li-Sommer; Michael Brands; Mario Lobell; Adrian Tersteegen; Herbert M. Himmel; Karl-Heinz Schlemmer; Dieter Lang; Kirstin Petersen; Matthias Renz; Dominik Mumberg; Jens Hoffmann; Gerhard Siemeister; Ulf Boemer


Archive | 2008

Pyrazolopyridin-ethynylphenyl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same

Ingo Hartung; Hans Briem; Georg Kettschau; Karl-Heinz Thierauch; Ulf Boemer


Archive | 2007

2-Aryl-thiazol-4-carbonsäureamid-Derivate, deren Herstellung und Verwendung als Arzneimittel

Ulf Boemer; Ulrich Bothe; Gudith Guenther; Duy Nguyen; Bonin Arne Von


Archive | 2007

Neue 2-Hetarylthiazol-4-carbonsäureamid-Derivative, deren Herstellung und Verwendung als Arzneimittel

Ulf Boemer; Ulrich Bothe; Judith Guenther; Duy Nguyen; Bonin Arne Von

Collaboration


Dive into the Ulf Boemer's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Duy Nguyen

Bayer Schering Pharma AG

View shared research outputs
Top Co-Authors

Avatar

Ingo Hartung

Bayer HealthCare Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Anne Mengel

Bayer HealthCare Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar

Bonin Arne Von

Bayer HealthCare Pharmaceuticals

View shared research outputs
Researchain Logo
Decentralizing Knowledge